European standard clinical practice - Key issues for the medical care of individuals with familial leukemia.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 22 03 2022
revised: 02 02 2023
accepted: 10 02 2023
pubmed: 13 2 2023
medline: 8 3 2023
entrez: 12 2 2023
Statut: ppublish

Résumé

Although hematologic malignancies (HM) are no longer considered exclusively sporadic, additional awareness of familial cases has yet to be created. Individuals carrying a (likely) pathogenic germline variant (e.g., in ETV6, GATA2, SAMD9, SAMD9L, or RUNX1) are at an increased risk for developing HM. Given the clinical and psychological impact associated with the diagnosis of a genetic predisposition to HM, it is of utmost importance to provide high-quality, standardized patient care. To address these issues and harmonize care across Europe, the Familial Leukemia Subnetwork within the ERN PaedCan has been assigned to draft an European Standard Clinical Practice (ESCP) document reflecting current best practices for pediatric patients and (healthy) relatives with (suspected) familial leukemia. The group was supported by members of the German network for rare diseases MyPred, of the Host Genome Working Group of SIOPE, and of the COST action LEGEND. The ESCP on familial leukemia is proposed by an interdisciplinary team of experts including hematologists, oncologists, and human geneticists. It is intended to provide general recommendations in areas where disease-specific recommendations do not yet exist. Here, we describe key issues for the medical care of familial leukemia that shall pave the way for a future consensus guideline: (i) identification of individuals with or suggestive of familial leukemia, (ii) genetic analysis and variant interpretation, (iii) genetic counseling and patient education, and (iv) surveillance and (psychological) support. To address the question on how to proceed with individuals suggestive of or at risk of familial leukemia, we developed an algorithm covering four different, partially linked clinical scenarios, and additionally a decision tree to guide clinicians in their considerations regarding familial leukemia in minors with HM. Our recommendations cover, not only patients but also relatives that both should have access to adequate medical care. We illustrate the importance of natural history studies and the need for respective registries for future evidence-based recommendations that shall be updated as new evidence-based standards are established.

Identifiants

pubmed: 36775010
pii: S1769-7212(23)00033-2
doi: 10.1016/j.ejmg.2023.104727
pii:
doi:

Substances chimiques

Transcription Factors 0
SAMD9 protein, human 0
Intracellular Signaling Peptides and Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104727

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

Alisa Förster (A)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Claudia Davenport (C)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Nicolas Duployez (N)

Department of Hematology, CHU Lille, INSERM, University Lille, Lille, France.

Miriam Erlacher (M)

Division of Pediatric Hematology-Oncology, Department of Pediatric and Adolescent Medicine, University of Freiburg, Freiburg, Germany.

Alina Ferster (A)

Department of Pediatric Rheumatology, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.

Jude Fitzgibbon (J)

Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Gudrun Göhring (G)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Henrik Hasle (H)

Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.

Marjolijn C Jongmans (MC)

Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.

Alexandra Kolenova (A)

Department of Pediatric Hematology and Oncology, Comenius University Medical School and University Children's Hospital, Bratislava, Slovakia.

Geertruijte Kronnie (G)

Department of Women's and Children's Health, University of Padova, Italy.

Tim Lammens (T)

Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

Cristina Mecucci (C)

Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.

Wojciech Mlynarski (W)

Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.

Charlotte M Niemeyer (CM)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Francesc Sole (F)

Josep Carreras Leukemia Research Institute (IJC), Campus ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Tomasz Szczepanski (T)

Polish Pediatric Leukemia/Lymphoma Study Group, Zabrze, Poland; Medical University of Silesia, Katowice, Poland.

Esmé Waanders (E)

Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Andrea Biondi (A)

Clinica Pediatrica and Centro Ricerca Tettamanti, Università di Milano-Bicocca, Monza, Italy.

Marcin Wlodarski (M)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Brigitte Schlegelberger (B)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Tim Ripperger (T)

Department of Human Genetics, Hannover Medical School, Hannover, Germany. Electronic address: ripperger.tim@mh-hannover.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH